Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial

C. B. Reeder, D. E. Reece, V. Kukreti, C. Chen, S. Trudel, J. Hentz, B. Noble, N. A. Pirooz, J. E. Spong, J. G. Piza, V. H.J. Zepeda, J. R. Mikhael, J. F. Leis, P. L. Bergsagel, R. Fonseca, A. K. Stewart